The anti-malarial drug atovaquone potentiates platinum-mediated cancer cell death by increasing oxidative stress.
Ontology highlight
ABSTRACT: Platinum chemotherapies are highly effective cytotoxic agents but often induce resistance when used as monotherapies. Combinatorial strategies limit this risk and provide effective treatment options for many cancers. Here, we repurpose atovaquone (ATQ), a well-tolerated & FDA-approved anti-malarial agent by demonstrating that it potentiates cancer cell death of a subset of platinums. We show that ATQ in combination with carboplatin or cisplatin induces striking and repeatable concentration- and time-dependent cell death sensitization in vitro across a variety of cancer cell lines. ATQ induces mitochondrial reactive oxygen species (mROS), depleting intracellular glutathione (GSH) pools in a concentration-dependent manner. The superoxide dismutase mimetic MnTBAP rescues ATQ-induced mROS prod
SUBMITTER: Coates JTT
PROVIDER: S-EPMC7591508 | biostudies-literature | 2020
REPOSITORIES: biostudies-literature
ACCESS DATA